Handelsavisen
prelaunch
Companies ›Healthcare ›9546.SE
95
9546.SE — Tadawul Healthcare Facilities & Services

9546.Se

$49,50
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,67 %
Op margin
15,3 %
ROE
12,3 %
Net margin
13,6 %
Debt / equity
0,55
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.

Business. The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
12,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 9546.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 9546.SE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    The company maintains a debt-to-equity ratio of 0.55, indicating a moderate level of leverage, and a current ratio of 6.26, suggesting strong short-term liquidity. However, the company's free cash flow is negative at -41,181,320, which may signal potential liquidity constraints despite its high current ratio.

    In terms of profitability, the company reports a return on equity of 12.35% and a return on assets of 7.15%, which are key metrics for assessing performance in the healthcare industry. These figures suggest the company is generating returns above the industry median, indicating strong operational efficiency.

    The company's revenue is concentrated in its core operations, with no disclosed geographic or segment breakdown in the provided data. This lack of diversification may pose a risk if the company's primary market experiences downturns.

    The company's growth trajectory is not explicitly detailed in the provided data, but the negative free cash flow and significant capital expenditure of -77,328,870 suggest that the company is investing heavily in its operations, which could support future growth.

    The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in maintaining liquidity without external financing.

    Recent events, such as filings and transcripts, are not detailed in the provided data, so no specific recent developments can be cited.

    Key takeaways
    • The company has a strong current ratio of 6.26, indicating robust short-term liquidity.
    • The company's return on equity of 12.35% and return on assets of 7.15% suggest strong profitability.
    • The company is investing heavily in its operations, as evidenced by a capital expenditure of -77,328,870.
    • The company faces a medium liquidity risk due to its negative free cash flow and net cash position.
    • The company has a low dilution risk, indicating a stable capital structure.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $49,50
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $222.9M
    Net cashⓘ
    -$108.8M
    Current ratioⓘ
    6.3
    Debt / equityⓘ
    0.6
    ROAⓘ
    7.1%
    ROEⓘ
    12.3%
    Cash conversionⓘ
    97.0%
    CapEx / revenueⓘ
    -38.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin15,3 %Above median
    Net Margin13,6 %Above P75
    ROE12,3 %Above median
    Capex / Rev-38,3 %Bottom quartile
    D/E0,55Below median
    Cash Conv0,97Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 9546.SE Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    9546.SECanonical
    Tadawul · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage